Armata Pharmaceuticals Inc (ARMP)
2.59
+0.04
(+1.57%)
USD |
NYAM |
May 01, 13:14
Armata Pharmaceuticals Research and Development Expense (Quarterly): 7.928M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.928M |
| September 30, 2023 | 7.978M |
| June 30, 2023 | 8.259M |
| March 31, 2023 | 9.604M |
| December 31, 2022 | 9.569M |
| September 30, 2022 | 8.40M |
| June 30, 2022 | 9.02M |
| March 31, 2022 | 8.028M |
| December 31, 2021 | 4.814M |
| September 30, 2021 | 5.626M |
| June 30, 2021 | 5.225M |
| March 31, 2021 | 4.35M |
| December 31, 2020 | 4.98M |
| September 30, 2020 | 4.066M |
| June 30, 2020 | 2.648M |
| March 31, 2020 | 2.75M |
| December 31, 2019 | 1.668M |
| September 30, 2019 | 3.019M |
| June 30, 2019 | 3.076M |
| March 31, 2019 | 2.061M |
| December 31, 2018 | -8.263M |
| September 30, 2018 | 1.915M |
| June 30, 2018 | 1.692M |
| March 31, 2018 | 1.464M |
| December 31, 2017 | 1.09M |
| Date | Value |
|---|---|
| September 30, 2017 | -0.829M |
| June 30, 2017 | 1.13M |
| March 31, 2017 | 1.49M |
| December 31, 2016 | 0.802M |
| September 30, 2016 | 1.655M |
| June 30, 2016 | 1.241M |
| March 31, 2016 | 1.98M |
| December 31, 2015 | 1.215M |
| September 30, 2015 | 0.728M |
| June 30, 2015 | 1.077M |
| March 31, 2015 | 0.972M |
| December 31, 2014 | 1.113M |
| September 30, 2014 | 1.793M |
| June 30, 2014 | 1.888M |
| March 31, 2014 | 1.011M |
| December 31, 2013 | 1.11M |
| September 30, 2013 | 1.123M |
| June 30, 2013 | 3.595M |
| March 31, 2013 | 0.641M |
| September 30, 2009 | 1.515M |
| June 30, 2009 | 1.891M |
| March 31, 2009 | 2.12M |
| December 31, 2008 | 3.889M |
| September 30, 2008 | 3.192M |
| June 30, 2008 | 4.156M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.668M
Minimum
Dec 2019
9.604M
Maximum
Mar 2023
5.842M
Average
5.225M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 3.20M |
| Perspective Therapeutics Inc | 6.08M |
| Protalix BioTherapeutics Inc | 3.102M |
| Electromed Inc | 0.107M |
| Xtant Medical Holdings Inc | 0.492M |